Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. - Wikidata - awgldk - TriplyDB

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

http://www.wikidata.org/entity/Q52595727

about

T Cells: Soldiers and Spies--The Surveillance and Control of Effector T Cells by Regulatory T Cells Oral tolerance to food protein The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD.Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid Unique properties of thymic antigen-presenting cells promote epigenetic imprinting of alloantigen-specific regulatory T cells.SOCS1 and regulation of regulatory T cells plasticity.Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions Shift of graft-versus-host-disease target organ tropism by dietary vitamin A.Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Optimal isolation of functional Foxp3+ induced regulatory T cells using DEREG mice.Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease Antigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance.Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice.HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.Regulatory T Cells Resist Cyclosporine-Induced Cell Death via CD44-Mediated Signaling Pathways.IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localization Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?Polyclonal CD4+Foxp3+ Treg cells induce TGFβ-dependent tolerogenic dendritic cells that suppress the murine lupus-like syndrome.TGF-β-Induced Regulatory T Cells Directly Suppress B Cell Responses through a Noncytotoxic Mechanism Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive?CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in mice Peripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and function Regulatory T-Cell Therapy for Graft-versus-host Disease.Treatment of graft-versus-host disease with naturally occurring T regulatory cells.Prevention of allogeneic cardiac graft rejection by transfer of ex vivo expanded antigen-specific regulatory T-cells.Regulatory T cells for the prevention of graft-versus-host disease: professionals defeat amateurs.Regulatory T cells and IL-17-producing cells in graft-versus-host disease.Clinical perspectives for regulatory T cells in transplantation tolerance.Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation.The role of regulatory T cells in the biology of graft versus host disease.Potential and limitations of regulatory T-cell therapy in solid organ transplantation.Intestinal mucosal tolerance and impact of gut microbiota to mucosal tolerance The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy

P2860

Q26823613-F67E5E03-7BE6-47BA-9A9C-983D1B904035 Q27026259-A7B67F42-BB06-4347-AEDF-6A148CA55453 Q28066083-6A798FAD-C506-40D5-BBAC-97AF5984F355 Q28072627-55C8548A-117A-4B3C-B752-0AB3D3A32580 Q28743652-A61E5AEF-3881-445E-85B3-0102CF4A6C5F Q30573584-67DFDC58-CB88-4E66-B48F-66BBB74482CE Q33778359-0EB57916-A3C5-4AA7-BFD3-BB90EB92E5EB Q33829220-5DC83BC0-B4A1-421F-A527-A54C523E53F6 Q34009286-73015280-0EA1-4AEF-B18B-80641B57DBB4 Q34248531-CE288FA6-57AD-49F0-B878-7FFD43CF855C Q34292981-C19F2E7E-1558-4624-9A65-27105569A501 Q34293038-D82119A7-B40C-4A37-9087-958227E7F0CE Q34408309-4A358F8F-A44E-49F1-AF17-B6822B530B46 Q35053246-52D3186B-1D68-49C6-B8DD-F303FF8D421F Q35190507-5B91588C-1C9B-43F2-95FC-33BF789225E3 Q35669076-EA2889AD-B27A-4968-B57A-395FD94B435E Q35815893-286945CC-D823-4A25-89FC-8609FC683479 Q35926395-5F92D466-5598-453E-A3A8-FA965231F971 Q36015241-D2B7CDAE-51B5-4D45-95C2-475C247CD788 Q36089251-10BEADED-1260-4070-9BA0-E337B1A13041 Q36200557-19B58114-B788-45C8-A074-614929967481 Q36378864-87405EF6-E8D3-45F0-B3C1-9041A387DDE3 Q36470364-B6DA8854-154C-4F44-B677-C964843702DA Q36905992-FA0084F3-1B93-44FB-B87F-16CC29E2B5BB Q37021703-5D609D5D-0360-4AB9-B2F0-9E1BD34E3F46 Q37079114-E771CA5D-D4F6-4D1B-A136-1A0C7A25B50A Q37122171-5678D043-E530-47E8-99A1-39954C2EE8C6 Q37309438-02D6347E-FA70-4C7D-88BA-E4E3F1546235 Q37321716-A528128E-72B9-4A94-A0A3-1756D4492B6E Q37548930-C1BE2C0F-A99D-4433-AC0B-EBBD93F6105E Q37624578-B72E0737-C77D-42BB-B81D-792D65AF83A6 Q37900645-A43BEF57-CBB8-484F-AAD3-48B6B0387291 Q37912653-B123D566-9C55-40D9-95AA-29595A94AE2A Q38000048-19D7F03E-48D0-4E16-8E3A-25C579DD8A0E Q38095964-B6AAB102-A885-4F32-9BFD-921DE07988EB Q38117369-56711FE0-B2AC-4B69-AD8E-BD972D36D6A2 Q38235166-403A2921-E429-482D-9619-E4D29A9304CF Q38335183-AAC310E0-0E64-4D32-9890-550859BA72F0 Q39012031-E89CA55A-FB89-43AC-9B9C-1502D07B4970 Q39559727-E93506D8-A513-483D-B6D1-7AFCABF27707

P2860

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

http://www.wikidata.org/entity/Q52595727

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Alloantigen-specific de novo-i ...... rotect from experimental GVHD.

@en

Alloantigen-specific de novo-i ...... rotect from experimental GVHD.

@nl

type

label

Alloantigen-specific de novo-i ...... rotect from experimental GVHD.

@en

Alloantigen-specific de novo-i ...... rotect from experimental GVHD.

@nl

prefLabel

Alloantigen-specific de novo-i ...... rotect from experimental GVHD.

@en

Alloantigen-specific de novo-i ...... rotect from experimental GVHD.

@nl

P1433

Q52595727-37FA8B22-2B64-4318-8850-FE0D9EAAF9D5

P1476

Q52595727-7CCE1891-81B1-40C8-8ED4-909472EA2D68

P2093

Q52595727-0DA2DB34-69EF-47C2-9392-90BF0908EAB8

Q52595727-0DF1C546-CE8C-47DB-85B7-D8E61E32DD96

Q52595727-1CF920AB-48A2-4970-BF77-C0D14934BB3A

Q52595727-2B7E7B7E-6FB4-4FAC-89F5-4326C81AAC7D

Q52595727-5F9C46BF-8011-461E-B57C-A23FF11805E6

P2860

Q52595727-050458DC-28C7-46B2-81E3-460CAA43CBC2

Q52595727-20B18986-02AE-47D3-A6BC-3FC8935CCF4A

Q52595727-3687EB94-39A5-46E2-8C20-16C46B53A014

Q52595727-7DEBC94F-83E0-49DF-9EE3-08E98F0B692C

P304

Q52595727-9D8EE086-7FDF-4633-9BD8-204F60F65005

P31

Q52595727-5E229187-CE8A-42BA-9695-3C2A5D5D749A

P356

Q52595727-F2FD4ED5-5010-434F-82EE-C0A6F909551E

P407

Q52595727-6CCAECFE-36D6-4EE7-8004-3AEC86D3F213

P433

Q52595727-C0966D8C-EA68-4E7C-B43D-EAFD29A0116A

P478

Q52595727-B171E9FB-C894-455D-8CCA-B80FCE61969C

P50

Q52595727-2D3A7021-C16C-4C09-9628-2733C9422749

Q52595727-9035AEE4-9DBE-4EED-A6B6-55F286161E42

Q52595727-B131CE60-A0C8-4BA8-BE5B-D9CA7D6D8916

Q52595727-D8406A43-B4AC-46E7-8594-1C1D653AAF18

Q52595727-E33A17A4-D247-46C1-8D24-B594A5FCD17C

P577

Q52595727-AAFAAC61-B218-41E0-BF8A-1181B2BD0D4E

P5875

Q52595727-02773358-9EE9-407A-8858-96E2E6EC48B7

P698

Q52595727-CCF4022E-CF32-4C6E-A412-157332AE6FF2

P356

P1433

European Journal of Immunology

P1476

Alloantigen-specific de novo-i ...... protect from experimental GVHD

@en

P2093

Anja Bubke

http://www.w3.org/2001/XMLSchema#string

Arnold Ganser

http://www.w3.org/2001/XMLSchema#string

Jochen Huehn

http://www.w3.org/2001/XMLSchema#string

Niklas Czeloth

http://www.w3.org/2001/XMLSchema#string

Susanne Schmitz

http://www.w3.org/2001/XMLSchema#string

P2860

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7

Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia

Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6.

Th2 lymphoproliferative disorder of LatY136F mutant mice unfolds independently of TCR-MHC engagement and is insensitive to the action of Foxp3+ regulatory T cells.

P304

3091-3096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJI.200939432

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Malissen

Christian Koenecke

Adrien Kissenpfennig

Reinhold Forster

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26808549

http://www.w3.org/2001/XMLSchema#string

P698

19750478

http://www.w3.org/2001/XMLSchema#string